Latest Advances in Cardiometabolic Treatment Include Potential New Indications for Metabolic Surgery, New Drug Development

Topic: Obesity/Weight Management Diabetes Management date: 10/23/2015 Featured Expert: Robert Eckel, MD

In an interview conducted at the 10th Annual Cardiometabolic Health Congress, CMHC co-chair Dr. Robert Eckel, of the University of Colorado Anschutz Medical Campus, spoke about the promise of bariatric surgery as not only a strategy for obesity management but diabetes as well, referring to follow-up data of a trial in which many patients who underwent surgery no longer had diabetes 5 years later.

Another area of advancement is in new drug development, Dr. Eckel continued. High doses of the T2DM drug liraglutide have been shown to be associated with “a promising amount of weight reduction” in patients without diabetes.

See the full interview here.